DiaCarta

Richmond, United States Founded: 2011 • Age: 15 yrs
In vitro diagnostic tests for precision medicine are provided.

About DiaCarta

DiaCarta is a Healthcare company based in Richmond (United States) founded in 2011. In vitro diagnostic tests for precision medicine are provided. DiaCarta has raised $53 million across 3 funding rounds from investors including HHS, Fortune Fountain Capital and BioVeda China Fund. DiaCarta offers products and services including RadTox cfDNA Test, ColoScape Test, Oncuria Bladder Cancer Test, and QuantiVirus SARS-CoV-2 Test. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is DiaCarta, Inc. Its competitors include Guardant Health, Natera and Denali Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

DiaCarta was founded in 2011 and is based in Richmond, United States. In vitro diagnostic tests for precision medicine are developed within the biotechnology sector. The proprietary QClamp platform is employed, featuring a sequence-specific xeno-nucleic acid clamp that suppresses wild-type DNA. This enables detection of oncogenic tumor drivers and therapy resistance. Additional technologies include SuperbDNA for cervical cancer testing and multiplex barcoding for DigiPlex genotyping assays.

  • Headquarters Richmond, United States
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website diacarta.com
  • Social LinkedIn X Facebook
  • Legal Name Diacarta, Inc.
Key Metrics
  • Total Equity Funding
    $53M (USD)

    in 3 rounds

  • Latest Funding Round
    $45M (USD), Series B

    Feb 2018

  • Investors
    HHS

    & 2 more

Products & Services of DiaCarta

DiaCarta offers a comprehensive portfolio of products and services, including RadTox cfDNA Test, ColoScape Test, Oncuria Bladder Cancer Test, and QuantiVirus SARS-CoV-2 Test.

RadTox cfDNA Test
Cancer Monitoring

Monitors cancer treatment response through circulating DNA analysis.

ColoScape Test
Colorectal Cancer Screening

Detects colorectal cancer via DNA-based screening methods.

Oncuria Bladder Cancer Test
Bladder Cancer Detection

Identifies bladder cancer markers for early diagnosis.

QuantiVirus SARS-CoV-2 Test
Infectious Disease Testing

Detects COVID-19 virus through PCR-based methods.

Funding Insights of DiaCarta

DiaCarta has successfully raised a total of $53M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $45 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $53M
  • Total Rounds 3
  • Last Round Series B β€” $45M
  • First Round $594,739

    (Mar 2012)

  • Investors Count 3

All 3 funding rounds of DiaCarta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2018$45MSeries B–Fortune Fountain Capital
–
Jan 2015$8MSeries A–BioVeda China Fund
–
Mar 2012$594,739Grant––
Valuation history

3 investors in total: 3 institutional.

Investors in DiaCarta

DiaCarta has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Fortune Fountain Capital and BioVeda China Fund.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
fortunefountaincapital.com
VC firm funding companies in China and the US
bvcf.comHuangpu, China
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for DiaCarta

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of DiaCarta

30 people are tracked at DiaCarta (15 in leadership, 6 in board & advisors, 9 in team).

NameRoleGroup
Dennis Gao
VP of Finance & Principle Financial OfficerLeadership
Zheng Li
VP, Clinical AffairsLeadership
King Lee
VP, RegulatoryLeadership
Michael Sha
CTO & SVP, R&DLeadership
Effie Ho
General Manager, Asia PacificLeadership
Anne K. Vallerga
VP, External AffairsLeadership
Aiguo Zhang
Founder, President & CEOLeadership
Mauro Scimia
Senior Director Of Business Development And Clinical, EuropeLeadership
Wei Liu
Vice President, Product Management And MarketingLeadership
Yuzhen Shi
Director HRLeadership
Michael Powell
Chief Scientific OfficerLeadership
Anne Vallerga
Vice President Of External AffairsLeadership
Rachel L Chuang
R&d DirectorLeadership
C. Mark Lu
CLIA Lab DirectorLeadership
Giselle A.
Director Of Business DevelopmentLeadership
Dean Tsao
Medical & Scientific AdvisorBoard & advisors
Walter Bodmer
Medical & Scientific AdvisorBoard & advisors
Anthony M. Magliocco
ChairBoard & advisors
Mickey Urdea
Medical & Scientific AdvisorBoard & advisors
Frank McCormick
Medical & Scientific AdvisorBoard & advisors

10 more people are available in the full profile.

Premium access

Complete people profiles for DiaCarta

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of DiaCarta

3 dated milestones of DiaCarta across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded DiaCarta is founded.
  2. Funding First funding round of $595K.
  3. Funding Latest funding round, Series B, of $45.0M.

Competitors of DiaCarta

DiaCarta has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Denali Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
guardanthealth.com2012Redwood, United States$557.5M1,351
Digital sequencing technology for cancer detection is developed.
natera.com2004Redwood, United States$152.1M3,293
Developer of cell-free DNA testing for oncology, women’s health, and organ health
denalitherapeutics.com2015San Francisco, United States$347M377
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
Premium access

Detailed competitors of DiaCarta

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of DiaCarta

The website of DiaCarta (diacarta.com) receives about 3.3K visits a month.

  • Monthly visits
    3.3K

    ▼ 4.8% vs previous month

Similar websites

Websites whose visitors overlap most with DiaCarta. Affinity shows how closely the audiences match.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as DiaCarta (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Diacarta

Premium access

Complete news archive for DiaCarta

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about DiaCarta

DiaCarta was founded in 2011 and raised its 1st funding round 1 year after it was founded.

DiaCarta is headquartered in Richmond, United States. It is registered at Richmond, Virginia, United States.

DiaCarta is a funded company, having raised a total of $53M across 3 funding rounds to date. The company's 1st funding round was a Grant of $594.74K, raised on Mar 2012.

DiaCarta was founded in 2011 and is based in Richmond, United States. In vitro diagnostic tests for precision medicine are developed within the biotechnology sector. The proprietary QClamp platform is employed, featuring a sequence-specific xeno-nucleic acid clamp that suppresses wild-type DNA. This enables detection of oncogenic tumor drivers and therapy resistance. Additional technologies include SuperbDNA for cervical cancer testing and multiplex barcoding for DigiPlex genotyping assays.

DiaCarta's top competitors include Guardant Health, Natera and Denali Therapeutics.

DiaCarta offers RadTox cfDNA Test, ColoScape Test, Oncuria Bladder Cancer Test, and QuantiVirus SARS-CoV-2 Test.

DiaCarta has 3 investors. Key investors include HHS, Fortune Fountain Capital, and BioVeda China Fund.

DiaCarta operates through Diacarta, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available